UFF
CBIO icon

USA Financial Formulas’s Crescent Biopharma CBIO Stock Holding History

USA Financial Formulas’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-341
Closed -$573K – 349
2017
Q4 		$573K Buy
+341
New +$451K 0.14% 120

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
OppenheimerFunds
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

USA Financial Formulas's CBIO Position: Q1 2018 in Review

USA Financial Formulas sold out of Crescent Biopharma (CBIO) in Q1 2018, closing a stake of 341 shares — an estimated $573K sold.

USA Financial Formulas first reported a position in CBIO in Q4 2017 and held it in 1 quarter. The position peaked at $573K in Q4 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q1 2018.

  • USA Financial Formulas reported no remaining Crescent Biopharma position as of Q1 2018 after selling out during the quarter.
  • USA Financial Formulas sold 341 Crescent Biopharma shares in Q1 2018, an estimated $573K.
  • USA Financial Formulas first reported a position in Crescent Biopharma in Q4 2017 and held it in 1 quarter.
  • USA Financial Formulas's Crescent Biopharma position peaked at $573K in Q4 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2018.

Based on USA Financial Formulas's 13F filing for Q1 2018, filed 3 Apr 2018.